High calibre appointments to accelerate commercial strategy for Personal KinetiGraph™ (PKG™) in key US market
Key executive staff bring extensive medical device commercialisation experience
Melbourne, Australia 28 May 2015: Mobile health technology company, Global Kinetics Corporation, has appointed two key executives to drive the company’s commercial strategy, following recent regulatory clearance to market the Personal KinetiGraph™ (PKG™) technology in the high value American market.
Medical device reimbursement expert Peter Lynch has taken the position of Head of Global Market Access. A former reimbursement leader at globally regarded Medtronic Diabetes, Mr Lynch will plan and execute GKC’s reimbursement activities in different jurisdictions around the globe, seeking recurrent funding from payors for the PKG.
Joining Peter on the executive team will be Phil Roeser, who has taken the position of Executive President, North America. Mr Roeser brings an extensive background of business development in medical device companies spanning 20 years - including executive roles in industry stalwarts Hill-Rom, Fresenius and Medtronic. At GKC, he will oversee sales and marketing of the PKG technology throughout North America.
GKC Managing Director Mr Andrew Maxwell said these high calibre appointments were critical to the company’s ambitious commercial strategy in the high value US market.
He commented: “These appointments are pivotal to executing our commercial strategy in this region and we are moving swiftly to ensure the world leading PKG technology is available to over one million people living with Parkinson’s in the USA. We are delighted that executives of this calibre have chosen to join our company. We are looking forward to aggressively recruiting other talented staff to join our company throughout America. ”
GKC’s lead product is the Personal Kinetigraph™ (PKG™), a first in class medical technology that provides decision support information to neurologists to assist them to manage the key disabling movement symptoms of Parkinson’s – providing better quality of life for People with Parkinson’s at a reduced cost to the healthcare system.
The product has achieved FDA clearance, CE Mark and TGA registration and is now available to more than 50,000 people living with Parkinson’s disease across the USA, Europe and the Asia-Pacific via specialty movement disorder clinics. For more information on the Parkinson’s KinetiGraph™ please go to www.globalkineticscorporation.com.au
About Global Kinetics Corporation
Global Kinetics Corporation (GKC) is a privately held technology company headquartered in Australia focused on globally commercialising its innovative movement disorder assessment technology, specifically for the assessment of Parkinson’s Disease symptoms. The company’s lead product is the Personal Kinetigraph™ (PKG™), a first in class medical technology that provides decision support information to neurologists to assist them to manage the key disabling movement symptoms of Parkinson’s – providing better quality of life for People with Parkinson’s at a reduced cost to the healthcare system. The PKG™ system includes a wrist worn device that automatically records motion data. This data is downloaded within minutes, analysed and presented as a medical report that assists doctors to assess and manage movement disorder symptoms.
Parkinson’s disease is a progressive disorder of the brain’s frontal lobe, which controls impulsive and non-impulsive movement. An estimated 6 million people around the world are affected. The main motor (or movement) related symptoms of Parkinson’s disease are bradykinesia, rigidity, tremors, postural instability and over time people with Parkinson’s may experience dyskinesias or relentless uncontrolled movements. Other non-movement symptoms may be experienced such as speech and swallowing difficulties, cognitive impairment or behavioural change and sleep disturbance.
Help employers find you! Check out all the jobs and post your resume.
